In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Ligand Pharmaceuticals’ fair value at $2,522.38 greatly exceeds its current price of $303.39, indicating substantial implied upside; however, the Monte Carlo analysis suggests downside risk with all scenarios below the current price and a median value near $44. Analyst targets are closer to the market price, signaling valuation uncertainty. Financial health is strong, but wide valuation disparities highlight elevated risk and opportunity volatility.